Skip to main content

Neuphoria Therapeutics Inc.

corporate_fare Company Profile

Neuphoria Therapeutics Inc.

NEUP·NASDAQ·Life Sciences·CIK 0001191070

Neuphoria Therapeutics Inc. is a Delaware corporation and a clinical-stage biotechnology company. Following the results of its Phase 3 AFFIRM-1 trial and restructuring actions taken during fiscal 2026, the company's activities are focused on completing a proposed merger with Scancell Holdings plc ("Scancell"), preserving cash, maintaining public-company and contractual obligations, and managing intellectual property and economic interests in partnered programs. Neuphoria Therapeutics Inc. is currently conducting limited active internal research and development activities focused on its alpha7 nicotinic acetylcholine receptor negative allosteric modulator portfolio. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. On October 20, 2025, the company announced that AFFIRM-1, its Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder ("SAD"), did not meet its primary endpoint, and secondary endpoint analysis did not show statistically significant differences or improvement over placebo. The BNC210 SAD program was discontinued, and the planned AFFIRM-2 trial was not initiated. The company subsequently maintained clinical readiness of the BNC210 program for post-traumatic stress disorder ("PTSD") but paused the planned SYMPHONY Phase 2b/3 trial pending a strategic transaction review process and subsequent planned merger transaction with Scancell. During fiscal 2026, Neuphoria Therapeutics Inc. terminated its facility leases, retained only one full-time employee, and canceled, paused, or deferred major internal research and development activities, including preclinical programs. The company continues to operate in the ordinary course with support from personnel via consulting arrangements and external support, including legal, accounting, and an interim CEO. Additionally, partners continue programs independently, including Merck's alpha7 receptor positive allosteric modulator ("PAM") program, the KAT6 program licensed by the former Cancer Therapeutics Cooperative Research Centre ("CTx CRC") to Pfizer Inc., and Carina Biotech's ("Carina") CNA3103 program.

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for NEUP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-18, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NEUP spans 10-K, DEFA14A, 8-K, 10-Q.

Recent high-impact activity:

  • Neuphoria 10-K Reveals Material Weakness, $5.4M Goodwill Impairment, and Restructuring Details
  • Neuphoria Enters All-Share Merger with Scancell, Backed by $53.6M+ Financing
  • Neuphoria Enters All-Share Merger with Scancell; Combined Company to Focus on Immuno-Oncology
  • Neuphoria Agrees to All-Share Merger with Scancell, $89M Financing Secured
  • Neuphoria Therapeutics Confirms Acquisition Discussions with Scancell

Financial Snapshot

Fiscal year ended June 30, 2026
Revenue
$1.17M
Net Income
-$13.45M
Diluted EPS
-$3.06
Op. Cash Flow
-$12.35M
Operating Income
-$16.45M
Cash & Equivalents
$19.87M
Debt / Equity
0.00×
Net Margin
-11.46×
Shares Outstanding
5.41M sh
Source: 10-K · filed 2026-09-18 · accession 0001193125-26-395536

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 12,377 shares in NEUP as of the October 30, 2026 settlement, a 92.5% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 53.7% of NEUP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,377 shares as of October 30, 2026
Change vs prior period▲ 92.5%
Days to cover1.00 at avg daily volume of 37,998
Daily short volume (FINRA facilities)53.7% of 11,837 shares on November 20, 2026
5-day average short volume37.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with N →
$2.35
52-week range · as of 2026-09-18 $2.35 – $21.4
Market cap
$12.72M
Volume
56K (1.7× avg)
3-mo avg 33.6K
Live data · 2026-11-22 06:04 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NEUP - Latest Insights

NEUP
Sep 18, 2026, 4:10 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.70
Real-time Price: $2.35 info
Change: -$1.35 (-36%) info
Market Cap: $12.717M info
NEUP
Jul 23, 2026, 6:39 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $3.73
Real-time Price: $2.35 info
Change: -$1.38 (-37%) info
Market Cap: $12.717M info
NEUP
Jul 23, 2026, 6:37 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.73
Real-time Price: $2.35 info
Change: -$1.38 (-37%) info
Market Cap: $12.717M info
NEUP
Jul 23, 2026, 6:13 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $3.98
Real-time Price: $2.35 info
Change: -$1.63 (-41%) info
Market Cap: $12.717M info
NEUP
Jun 26, 2026, 4:41 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $4.59
Real-time Price: $2.35 info
Change: -$2.24 (-49%) info
Market Cap: $12.717M info
NEUP
May 26, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.46
Real-time Price: $2.35 info
Change: -$3.11 (-57%) info
Market Cap: $12.717M info
NEUP
May 16, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $4.75
Real-time Price: $2.35 info
Change: -$2.40 (-51%) info
Market Cap: $12.717M info
NEUP
May 15, 2026, 8:33 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.10
Real-time Price: $2.35 info
Change: -$2.75 (-54%) info
Market Cap: $12.717M info
NEUP
Feb 17, 2026, 3:57 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.05
Real-time Price: $2.35 info
Change: -$1.70 (-42%) info
Market Cap: $12.717M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets